Diagnostic yield, safety and therapeutic consequences of myocardial biopsy in clinically suspected fulminant myocarditis unweanable from mechanical circulatory support.
Clinically suspected myocarditis
Diagnostic yield
Endomyocardial biopsy
Extracorporeal membrane oxygenation
Fulminant myocarditis
Mechanical circulatory support
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
31 Aug 2023
31 Aug 2023
Historique:
received:
11
03
2023
accepted:
03
08
2023
medline:
1
9
2023
pubmed:
1
9
2023
entrez:
31
8
2023
Statut:
epublish
Résumé
Fulminant myocarditis is a rare and severe disease whose definite and etiological diagnoses rely on pathological examination. Albeit, myocardial biopsy can be associated with significant morbidity and mortality, its therapeutic consequences are unclear. We conducted a study to determine the diagnostic yield, the safety and the therapeutic consequences of myocardial biopsy in patients with fulminant clinically suspected myocarditis unweanable from mechanical circulatory support (MCS). Monocenter, retrospective, observational cohort study in a 26-bed French tertiary ICU between January 2002 and February 2019. Inclusion of all fulminant clinically suspected myocarditis patients undergoing in-ICU myocardial biopsy while being on MCS. The primary endpoint was the proportion of patients classified as definite myocarditis using Bonaca criteria before and after including myocardial biopsy results. Forty-seven patients (median age 41 [30-47], female 53%) were included: 55% died before hospital discharge, 34% could be bridged-to-recovery and 15% bridged-to-transplant. Myocardial biopsy was endomyocardial or surgical in 36% and 64% cases respectively. Tamponade requiring emergency pericardiocentesis occurred in 29% patients after endomyocardial biopsy. After adding the biopsy results in the Bonaca classification algorithm the percentage of definite myocarditis raised from 13 to 55% (p < 0.0001). The rate of biopsy-related treatments modifications was 13%, leading to patients' recovery in only 4% patients. In clinically suspected myocarditis unweanable from MCS, myocardial biopsy increased the rate of definite myocarditis but was associated with a low rate of treatment modification and a significant proportion of adverse events. We believe the benefit/risk ratio of myocardial biopsy should be more carefully weighted in these frail and selected patients than suggested by actual guidelines. Further prospective studies are now needed to determine its value in patients under MCS.
Sections du résumé
BACKGROUND
BACKGROUND
Fulminant myocarditis is a rare and severe disease whose definite and etiological diagnoses rely on pathological examination. Albeit, myocardial biopsy can be associated with significant morbidity and mortality, its therapeutic consequences are unclear. We conducted a study to determine the diagnostic yield, the safety and the therapeutic consequences of myocardial biopsy in patients with fulminant clinically suspected myocarditis unweanable from mechanical circulatory support (MCS).
METHODS
METHODS
Monocenter, retrospective, observational cohort study in a 26-bed French tertiary ICU between January 2002 and February 2019. Inclusion of all fulminant clinically suspected myocarditis patients undergoing in-ICU myocardial biopsy while being on MCS. The primary endpoint was the proportion of patients classified as definite myocarditis using Bonaca criteria before and after including myocardial biopsy results.
RESULTS
RESULTS
Forty-seven patients (median age 41 [30-47], female 53%) were included: 55% died before hospital discharge, 34% could be bridged-to-recovery and 15% bridged-to-transplant. Myocardial biopsy was endomyocardial or surgical in 36% and 64% cases respectively. Tamponade requiring emergency pericardiocentesis occurred in 29% patients after endomyocardial biopsy. After adding the biopsy results in the Bonaca classification algorithm the percentage of definite myocarditis raised from 13 to 55% (p < 0.0001). The rate of biopsy-related treatments modifications was 13%, leading to patients' recovery in only 4% patients.
CONCLUSIONS
CONCLUSIONS
In clinically suspected myocarditis unweanable from MCS, myocardial biopsy increased the rate of definite myocarditis but was associated with a low rate of treatment modification and a significant proportion of adverse events. We believe the benefit/risk ratio of myocardial biopsy should be more carefully weighted in these frail and selected patients than suggested by actual guidelines. Further prospective studies are now needed to determine its value in patients under MCS.
Identifiants
pubmed: 37653258
doi: 10.1186/s13613-023-01169-y
pii: 10.1186/s13613-023-01169-y
pmc: PMC10471530
doi:
Types de publication
Journal Article
Langues
eng
Pagination
78Informations de copyright
© 2023. La Société de Réanimation de Langue Francaise = The French Society of Intensive Care (SRLF).
Références
Circulation. 2022 Feb;145(5):345-356
pubmed: 34865500
Circulation. 2010 Aug 31;122(9):900-9
pubmed: 20713901
JACC Cardiovasc Imaging. 2017 Jul;10(7):826-827
pubmed: 28017385
Circulation. 2020 Sep 29;142(13):1249-1260
pubmed: 32791857
Circulation. 2019 Jul 02;140(2):80-91
pubmed: 31390169
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
Circulation. 2008 Aug 5;118(6):639-48
pubmed: 18645053
Eur J Heart Fail. 2021 Jun;23(6):854-871
pubmed: 34010472
J Am Coll Cardiol. 2019 Jul 23;74(3):299-311
pubmed: 31319912
Circulation. 2020 Feb 11;141(6):e69-e92
pubmed: 31902242
J Am Coll Cardiol. 2022 Jul 26;80(4):299-312
pubmed: 35863846
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176
pubmed: 30545455
Circulation. 2022 Apr 12;145(15):1123-1139
pubmed: 35404682
J Card Fail. 2018 May;24(5):337-341
pubmed: 29626516
J Am Coll Cardiol. 2007 Nov 6;50(19):1914-31
pubmed: 17980265
Ann Intern Med. 2020 Apr 7;172(7):502-504
pubmed: 31842206
Circ Heart Fail. 2021 Aug;14(8):e008387
pubmed: 34344163
Circ Genom Precis Med. 2020 Aug;13(4):e002744
pubmed: 32522011
Transl Respir Med. 2014 Feb 13;2:4
pubmed: 25505696
Int J Cardiol. 2018 Feb 15;253:105-112
pubmed: 29306448
Circulation. 2017 Aug 8;136(6):529-545
pubmed: 28576783
Circ Genom Precis Med. 2023 Feb;16(1):e003672
pubmed: 36580316
Circ Heart Fail. 2013 Jul;6(4):676-84
pubmed: 23733916
Eur Heart J. 2022 Nov 1;43(41):4229-4361
pubmed: 36017568
Circulation. 2016 Dec 6;134(23):e579-e646
pubmed: 27832612